

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gout | D006073 | EFO_0004274 | M10 | 6 | 5 | — | — | — | 10 |
| Asymptomatic diseases | D058070 | — | — | 1 | 1 | — | — | — | 1 |
| Hyperuricemia | D033461 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Drug common name | VERINURAD |
| INN | verinurad |
| Description | Verinurad is a selective URAT1 inhibitor developed for gout and heart failure by AstraZeneca.
|
| Classification | Small molecule |
| Drug class | urate transporter inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(=O)O |
| PDB | — |
| CAS-ID | 1352792-74-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707347 |
| ChEBI ID | — |
| PubChem CID | 54767229 |
| DrugBank | DB11873 |
| UNII ID | 12WJ62D047 (ChemIDplus, GSRS) |
